Adicet Bio, Inc. — Director's Dealing 2023

Aug 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2023-08-14

Reporting Person: Schor Chen (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-14	Stock Option (Right to Buy)	$8.89	D	36857	Disposed	2029-12-05	Common Stock (36857)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	36857	Acquired	2029-12-05	Common Stock (36857)	Direct
2023-08-14	Stock Option (Right to Buy)	$16.11	D	872111	Disposed	2030-09-16	Common Stock (872111)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	872111	Acquired	2030-09-16	Common Stock (872111)	Direct
2023-08-14	Stock Option (Right to Buy)	$13.27	D	240000	Disposed	2031-01-12	Common Stock (240000)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	240000	Acquired	2031-01-12	Common Stock (240000)	Direct
2023-08-14	Stock Option (Right to Buy)	$16.82	D	421600	Disposed	2031-02-11	Common Stock (421600)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	421600	Acquired	2031-02-11	Common Stock (421600)	Direct
2023-08-14	Stock Option (Right to Buy)	$15.52	D	295000	Disposed	2032-01-06	Common Stock (295000)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	295000	Acquired	2032-01-06	Common Stock (295000)	Direct
2023-08-14	Stock Option (Right to Buy)	$9.05	D	384900	Disposed	2033-01-23	Common Stock (384900)	Direct
2023-08-14	Stock Option (Right to Buy)	$2.14	A	384900	Acquired	2033-01-23	Common Stock (384900)	Direct

Footnotes

F1: Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020.

F2: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3: The shares subject to this option are fully vested and exercisable as of the date hereof.

F4: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F5: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

F6: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

F7: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

F8: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

F9: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.